Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

CNS 3

Conditions

Carcinoma, Non-Small-Cell Lung 27Prostatic Neoplasms 26Brain Neoplasms 23Lung Neoplasms 17Neoplasm Metastasis 15Breast Neoplasms 12Melanoma 9Carcinoma, Renal Cell 8Pancreatic Neoplasms 6Colorectal Neoplasms 6Carcinoma, Hepatocellular 4Urinary Bladder Neoplasms 3Neoplasms 3NSCLC 3Meningioma 3Gastrointestinal Neoplasms 3Unresectable Locally Recurrent Rectal Cancer 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Spinal Cord Compression 2Small Cell Lung Carcinoma 2Sarcoma 2Hematologic Neoplasms 2Head and Neck Neoplasms 2Epidural Neoplasms 2Carcinoma, Transitional Cell 2Adenocarcinoma 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 5lutetium Lu 177 dotatate 4Specimen Handling 4Radiosurgery 3gallium Ga 68 dotatate 2Ga(III)-DOTATOC 2Bevacizumab 2regorafenib 1pembrolizumab 1olaparib 1neratinib 1capivasertib 1cabozantinib 1brigatinib 1abemaciclib 1X-Rays 1Watchful Waiting 1Tablets 1Surveys and Questionnaires 1Sunitinib 1Radiotherapy, Intensity-Modulated 1Protons 1Proton Therapy 1Photons 1Observation 1ONC206 1Nivolumab 1Mental Status and Dementia Tests 1Lysine 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Meningioma × Radiosurgery × 90 days × Clear all
NCT03604978 2026-05-13

Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
38 enrolled
CNS

Meningioma

NCT06466720 2026-05-04

CoDeB-Rad

University of Nottingham

Active not recruiting
80 enrolled
CNS

Brain Neoplasms, Meningioma, Cognitive Dysfunction

NCT04659811 2026-04-15

Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma

University of California, San Francisco

Phase 2 Active not recruiting
35 enrolled
CNS

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡